GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine with a copper ion) is a naturally occurring copper peptide found in human plasma, saliva, and urine. It is widely used in regenerative medicine, skincare, and hair care for its ability to stimulate collagen production, reduce inflammation, and accelerate wound healing.

Key Benefits

May support skin repair, collagen production, and reduction of visible aging signs
Commonly researched for promoting hair growth and improving hair follicle health
May help support wound healing and tissue regeneration
Research suggests potential benefits for reducing inflammation and improving skin elasticity

Order Now

FDA-Approved Uses

⚠️ NO FDA DRUG APPROVAL FOR ANY INDICATION ⚠️

GHK-Cu is NOT FDA-approved as an injectable or oral drug. It is widely used as a cosmetic ingredient (topical) in skincare, which is regulated separately under cosmetic law (not drug law). It occupies a regulatory grey area between cosmetics and drugs.

Regulatory status (2026):

Topical cosmetic use: Legal, regulated under MoCRA (Modernization of Cosmetics Regulation Act, effective 2024–2026)
Injectable compounding: Previously FDA Category 2 restricted; pending reclassification to Category 1 as of April 15, 2026 HHS announcement (PCAC review scheduled July 23–24, 2026)
Oral use: No FDA approval; unregulated

Conditions with clinical/research evidence (topical):

Skin aging: Wrinkle reduction, improved skin firmness, elastin/collagen stimulation
Wound healing / post-procedure recovery: Improved epithelial healing after laser resurfacing
Hair loss (alopecia): Scalp application to stimulate hair follicle activity
Scar remodeling: Reduction of scar tissue formation

Conditions under early investigation (injectable/systemic — not approved):

Anti-inflammatory conditions: Ulcerative colitis (animal/early data via SIRT1/STAT3 pathway)
Anti-aging / longevity: Genomic modulation of repair pathways (investigational)

Trade Names in USA and Manufacturers

No FDA-approved pharmaceutical trade name as injectable or oral drug.

Topical cosmetic products (numerous brands, not pharmaceutical-grade drugs):

Found in many skincare brands as ‘Copper Peptide GHK-Cu’ or ‘Tripeptide-1’ (INCI name)
Examples include products by NIOD, The Ordinary, Skin Biology, and others
These are cosmetic products, NOT FDA-approved drugs

Compounding pharmacies (injectable, with prescription):

Supplied by licensed 503A compounding pharmacies nationwide
Requires valid prescription from a licensed physician
No specific brand name; formulation varies by pharmacy

Original discovery: Biochemist Dr. Loren Pickart (1973)

Dosage

Topical (cosmetic, most clinically studied):

Concentration: 0.05% GHK-Cu in serum or cream
Application: Once or twice daily to affected skin areas
[Supported by 2023 split-face study n=60 and 2024 multicenter study]

Injectable (compounded, off-label, not FDA-approved):

Typical dose: 0.5–2 mg subcutaneously or intradermally, 1–3x/week
[Protocols vary widely by prescribing physician; no standardized protocol]

Scalp (hair loss, off-label):

Topical serum application to scalp 1–2x daily or
Mesotherapy injections to scalp (compounded formulation)

⚠️ No FDA-approved dosing protocol exists for any injectable or systemic use.

Pricing

Topical cosmetic products:
$20–$150/month (varies by brand and formulation)

Compounded injectable GHK-Cu (with prescription, 503A pharmacy):
~$100–$300/month depending on dose and pharmacy
Cash-pay only; not covered by insurance

Research peptide vendors (unregulated, not for human use):
~$30–$60 per vial

Coverage by Insurance Type

Topical cosmetic GHK-Cu: Not subject to drug insurance coverage (cosmetic product)

All formulations (injectable, systemic):

ACA Marketplace: Not covered
Employer Insurance: Not covered
Medicare: Not covered
Medicaid: Not covered
TRICARE: Not covered

All GHK-Cu use for medical indications is cash-pay only.

Tips

– For topical anti-aging or wound healing use: Look for products with 0.05% GHK-Cu (the concentration supported by clinical studies); verify product is from a reputable manufacturer.
– For post-procedure recovery: Ask your dermatologist or plastic surgeon whether a physician-prescribed compounded GHK-Cu formulation is appropriate after laser or surgery.
– For injectable use: As of May 2026, the pending PCAC review (July 2026) may reclassify GHK-Cu to Category 1 for 503A compounding — monitor FDA guidance updates.
– Avoid purchasing unregulated injectable GHK-Cu from grey-market sources; purity and sterility are not guaranteed.
– MoCRA compliance: Skincare brands using GHK-Cu as a cosmetic ingredient must now comply with FDA facility registration requirements (effective 2024–2026). Check brands for MoCRA compliance.
– Do not make drug claims about cosmetic GHK-Cu products — FDA enforcement is increasing against brands claiming ‘cellular repair’ or ‘collagen synthesis’ as drug effects.

Side Effects

Topical (well-established safety record):

Generally very well-tolerated
Mild skin irritation or redness at application site (uncommon)
Contact dermatitis (rare)
Copper excess risk is extremely low at topical cosmetic concentration.

Injectable (limited human data):

Injection site reactions: redness, swelling, bruising
Transient copper-related symptoms with excessive dosing (theoretical)
Hypersensitivity reactions (rare)

Systemic (unknown):
– Excess systemic copper accumulation: theoretical with high-dose injectable use; copper is an essential but potentially toxic trace element at excess levels
– Long-term injectable safety data not established in humans

Contraindications

No formal contraindications established (no approved drug label).

Based on pharmacology:
– Known copper hypersensitivity or allergy: Avoid — GHK-Cu is a copper complex
– Wilson’s disease (copper metabolism disorder): Avoid — copper accumulation risk
– Active skin infection or open wound (topical): Apply with caution; consult physician
– Pregnancy/breastfeeding (injectable): Insufficient safety data; not recommended
– Active malignancy (injectable/systemic): Theoretical concern due to angiogenic properties; caution advised

Pharmacology

GHK-Cu (Glycyl-L-Histidyl-L-Lysine:Copper(II)) is a naturally occurring tripeptide-copper complex found in human plasma (concentration ~200 ng/mL at age 20, declining to ~80 ng/mL at age 60), saliva, and urine. First isolated and characterized by biochemist Dr. Loren Pickart (1973). It consists of three amino acids (glycine, histidine, lysine) complexed with copper(II) ions.

MW ~340 Daltons (peptide portion). Copper is an essential trace element involved in collagen cross-linking, antioxidant enzymes (superoxide dismutase), and numerous enzymatic reactions.

The tripeptide-copper complex acts as a biological signal activating tissue repair and remodeling pathways. Plasma concentration declines significantly with age, correlating with reduced wound healing capacity and skin thinning.

Mechanism of action

GHK-Cu exerts effects through multiple pathways:

Genomic modulation (most significant mechanism):
Modulates expression of >31 genes associated with cellular repair, including genes involved in collagen/elastin synthesis, antioxidant defense, and inflammation control. Activates genes promoting tissue repair while suppressing pro-inflammatory and pro-fibrotic pathways.

Collagen and elastin synthesis:
Stimulates fibroblast production of collagen types I and III, elastin, and glycosaminoglycans — key components of skin and connective tissue.

Angiogenesis:
Promotes blood vessel formation — supports wound healing and tissue perfusion.

Antioxidant activity:
Copper component supports superoxide dismutase (SOD) activity; peptide itself has direct antioxidant properties.

Anti-inflammatory effects:
Suppresses pro-inflammatory cytokines (e.g., TNF-α, IL-6) in multiple tissue models.

Wound remodeling:
Activates metalloproteinases (MMPs) to remodel damaged extracellular matrix while simultaneously stimulating new matrix synthesis — a balanced tissue remodeling signal.

Result Claims By Different Companies

No pharmaceutical company marketing claims (no approved drug).

Academic/research findings (published studies):
– 2023 double-blind split-face RCT (n=60): 0.05% GHK-Cu serum demonstrated 22% increase in skin firmness and 16% reduction in fine lines vs. placebo over 12 weeks.
– 2024 multicenter clinical study: 25% faster epithelial recovery following laser skin resurfacing with GHK-Cu topical vs. control.
– 2025 preclinical study: Anti-inflammatory effects in ulcerative colitis model via SIRT1/STAT3 signaling pathway.
– Pickart & Margolina (2018, Life Sciences): Reviewed GHK-Cu as a ‘reset signal’ that restores gene expression of aging/damaged tissues toward a younger, healthier pattern.

⚠️ Most robust clinical evidence is for topical use. Injectable and systemic efficacy data in humans is limited. All claims for injectable use are off-label and not FDA-verified.

Disclaimer

This content about “GHK-Cu” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.